Biomarker discovery and development in pediatric critical care medicine

Pediatric Critical Care Medicine

Volumn 12, Issue 2, 2011, Pages 165-173

  Kaplan, Jennifer M ^a   Wong, Hector R ^b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

acute kidney injury; biomarker discovery and development; interleukin 8; multibiomarker based risk model; pediatric intensive care unit; pediatric septic shock; procalcitonin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE; FIBRINOGEN LIKE 2; GRANZYME B; HEAT SHOCK PROTEIN 70; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; LACTOFERRIN; LEUKOCYTE ELASTASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NEUTROPHIL COLLAGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OROSOMUCOID; PROCALCITONIN; PROTEIN; RESISTIN; SULFATASE; THROMBOSPONDIN 1; TROPONIN; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; HUMAN; INTENSIVE CARE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; SURVIVAL; VALIDATION PROCESS;

EID: 79953087339     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181e28876     Document Type: Review

References (60)

1. Biomarkers Definitions Working Group: Bio-markers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95
2. Marshall JC, Reinhart K: Biomarkers of sep-sis. Crit Care Med 2009; 37:2290-2298
3. Puntmann VO: How-to guide on biomarkers: Biomarker definitions, validation and appli-cations with examples from cardiovascular disease. Postgrad Med J 2009; 85:538-545
4. Ridker PM, Rifai N, Rose L, et al: Comparison of C-reactive protein and low-density lipo-protein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565 (Pubitemid 35315836)
5. Ridker PM, Cannon CP, Morrow D, et al: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28 (Pubitemid 40075677)
6. Ridker PM, Morrow DA, Rose LM, et al: Rel-ative efficacy of atorvastatin 80 mg and prav-astatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. JAm Coll Cardiol 2005; 45:1644-1648 (Pubitemid 40704500)
7. Sturgeon CM, Duffy MJ, Stenman UH, et al: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54:e11-e79 (Pubitemid 352777353)
8. Duffy MJ, Crown J: A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008; 54:1770-1779
9. Marshall JC: Sepsis: Rethinking the approach to clinical research. J Leukoc Biol 2008; 83: 471-482 (Pubitemid 351966853)
10. Rifai N, Gillette MA, Carr SA: Protein bio-marker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 2006; 24:971-983 (Pubitemid 44215392)
11. Wheeler DS, Devarajan P, Ma Q, et al: Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med 2008; 36:1297-1303 (Pubitemid 351482681)
12. Giuliano JS Jr, Lahni PM, Harmon K, et al: Admission angiopoietin levels in children with septic shock. Shock 2007; 28:650-654 (Pubitemid 350135468)
13. Wheeler DS, Lahni P, Odoms K, et al: Extra-cellular heat shock protein 60 (Hsp60) levels in children with septic shock. Inflamm Res 2007; 56:216-219 (Pubitemid 46985837)
14. Wheeler DS, Fisher LE Jr, Catravas JD, et al: Extracellular hsp70 levels in children with septic shock. Pediatr Crit Care Med 2005; 6:308-311 (Pubitemid 40724282)
15. Wong HR, Doughty LA, Wedel N, et al: Plasma bactericidal/permeability- increasing protein concentrations in critically ill chil-dren with the sepsis syndrome. Pediatr Infect Dis J1995; 14:1087-1091 (Pubitemid 26008462)
16. Wong HR, Carcillo JA, Burckart G, et al: Increased serum nitrite and nitrate concen-trations in children with the sepsis syn-drome. Crit Care Med 1995; 23:835-842
17. Anderson NL, Anderson NG: The human plasma proteome: history, character, and di-agnostic prospects. Mol Cell Proteomics 2002; 1:845-867
18. Haase M, Bellomo R, Devarajan P, et al: Ac-curacy of neutrophil gelatinase-associated li-pocalin (NGAL) in diagnosis and prognosis in acute kidney injury: A systematic review and meta-analysis. Am J Kidney Dis 2009; 54: 1012-1024
19. Devarajan P: Neutrophil gelatinase-associ-ated lipocalin (NGAL): A new marker of kid-ney disease. Scand J Clin Lab Invest Suppl 2008; 241:89-94 (Pubitemid 351883665)
20. Mishra J, Dent C, Tarabishi R, et al: Neutro-phil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238 (Pubitemid 40469655)
21. Mishra J, Ma Q, Prada A, et al: Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for isch-emic renal injury. J Am Soc Nephrol 2003; 14:2534-2543 (Pubitemid 37169339)
22. Devarajan P: Proteomics for biomarker dis-covery in acute kidney injury. Semin Neph-rol 2007; 27:637-651 (Pubitemid 350180173)
23. Snider RH Jr, Nylen ES, Becker KL: Procal-citonin and its component peptides in sys-temic inflammation: Immunochemical char-acterization. J Investig Med 1997; 45: 552-560 (Pubitemid 127806489)
24. Becker KL, Snider R, Nylen ES: Procalci-tonin in sepsis and systemic inflammation: A harmful biomarker and a therapeutic target. Br J Pharmacol 2010; 159:253-264
25. Assicot M, Gendrel D, Carsin H, et al: High serum procalcitonin concentrations in pa-tients with sepsis and infection. Lancet 1993; 341:515-518 (Pubitemid 23066085)
26. Linscheid P, Seboek D, Nylen ES, et al: In vitro and in vivo calcitonin I gene expression in parenchymal cells: A novel product of hu-man adipose tissue. Endocrinology 2003; 144:5578-5584 (Pubitemid 37476087)
27. Muller B, White JC, Nylen ES, et al: Ubiqui-tous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86:396-404 (Pubitemid 32109825)
28. Dandona P, Nix D, Wilson MF, et al: Procal-citonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605-1608
29. Brunkhorst FM, Eberhard OK, Brunkhorst R: Discrimination of infectious and noninfec-tious causes of early acute respiratory dis-tress syndrome by procalcitonin. Crit Care Med 1999; 27:2172-2176 (Pubitemid 29508332)
30. Uzzan B, Cohen R, Nicolas P, et al: Procalci-tonin as a diagnostic test for sepsis in criti-cally ill adults and after surgery or trauma: A systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003 (Pubitemid 43982479)
31. McMaster P, Park DY, Shann F, et al: Procal-citonin versus C-reactive protein and imma-ture-to-total neutrophil ratio as markers of infection after cardiopulmonary bypass in children. Pediatr Crit Care Med 2009; 10: 217-221
32. Simon L, Saint-Louis P, Amre DK, et al: Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med 2008; 9:407-413
33. Simon L, Gauvin F, Amre DK, et al: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis. Clin Infect Dis 2004; 39:206-217 (Pubitemid 38971491)
34. Castelli GP, Pognani C, Cita M, et al: Procal-citonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med 2009; 37:1845-1849
35. Tang BM, Eslick GD, Craig JC, et al: Accuracy of procalcitonin for sepsis diagnosis in criti-cally ill patients: Systematic review and meta-analysis. Lancet Infect Dis 2007; 7:210-217 (Pubitemid 46274517)
36. de Kruif MD, Limper M, Gerritsen H, et al: Additional value of procalcitonin for diagno-sis of infection in patients with fever at the emergency department. Crit Care Med 2010; 38:457-463
37. Rey C, Los Arcos M, Concha A, et al: Procal-citonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med 2007; 33:477-484 (Pubitemid 46333842)
38. Enguix A, Rey C, Concha A, et al: Compari-son of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 2001; 27: 211-215 (Pubitemid 32208990)
39. Olaciregui I, Hernandez U, Munoz JA, et al: Markers that predict serious bacterial infec-tion in infants under 3 months of age pre-senting with fever of unknown origin. Arch Dis Child 2009; 94:501-505
40. Han YY, Doughty LA, Kofos D, et al: Procal-citonin is persistently increased among chil-dren with poor outcome from bacterial sep-sis. Pediatr Crit Care Med 2003; 4:21-25
41. Hochreiter M, Kohler T, Schweiger AM, et al: Procalcitonin to guide duration of antibiotic therapy in intensive care patients: A random-ized prospective controlled trial. Crit Care 2009; 13:R83
42. Schuetz P, Christ-Crain M, Thomann R, et al: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The Pro-HOSP randomized controlled trial. JAMA 2009; 302:1059-1066
43. Bouadma L, Luyt CE, Tubach F, et al: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet 2010; 375:463-474
44. Tschoeke SK, Oberholzer A, Moldawer LL: Interleukin-18: A novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med 2006; 34:1225-1233
45. Rooney T, Roux-Lombard P, Veale DJ, et al: Synovial tissue and serum biomarkers of dis-ease activity, therapeutic response and radio-graphic progression: Analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis 2010; 69:706-714
46. Cusumano V, Midiri A, Cusumano VV, et al: Interleukin-18 is an essential element in host resistance to experimental group B strepto-coccal disease in neonates. Infect Immun 2004; 72:295-300 (Pubitemid 38018188)
47. Grobmyer SR, Lin E, Lowry SF, et al: Eleva-tion of IL-18 in human sepsis. J Clin Immunol 2000; 20:212-215
48. Oberholzer A, Steckholzer U, Kurimoto M, et al: Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. Shock 2001; 16:411-414 (Pubitemid 33598220)
49. Emmanuilidis K, Weighardt H, Matevossian E, et al: Differential regulation of systemic IL-18 and IL-12 release during postoperative sepsis: high serum IL-18 as an early predic-tive indicator of lethal outcome. Shock 2002; 18:301-305
50. Feezor RJ, Oberholzer C, Baker HV, et al: Molecular characterization of the acute in-flammatory response to infections with gram-negative versus gram-positive bacteria. InfectImmun 2003; 71:5803-5813 (Pubitemid 37205634)
51. Parikh CR, Devarajan P: New biomarkers of acute kidney injury. Crit Care Med 2008; 36(4 Suppl):S159-S165 (Pubitemid 351483046)
52. Parikh CR, Mishra J, Thiessen-Philbrook H, et al: Urinary IL-18 is an early predictive biomarker of acute kidney injury after car-diac surgery. Kidney Int 2006; 70:199-203 (Pubitemid 44000139)
53. Washburn KK, Zappitelli M, Arikan AA, et al: Urinary interleukin-18 is an acute kidney in-jury biomarker in critically ill children. Nephrol Dial Transplant 2008; 23:566-572 (Pubitemid 351767629)
54. Wong HR, Cvijanovich N, Wheeler DS, et al: Interleukin-8 as a stratification tool for in-terventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008; 178:276-282
55. Wong HR, Shanley TP, Sakthivel B, et al: Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics 2007; 30:146-155 (Pubitemid 47173278)
56. Nadel S, Goldstein B, Williams MD, et al: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III ran-domised controlled trial. Lancet 2007; 369: 836-843 (Pubitemid 46365900)
57. Nowak JE, Wheeler DS, Harmon KK, et al: Admission chemokine (C-C motif) ligand 4 levels predict survival in pediatric septic shock Pediatr Crit Care Med 2010; 11:213-216
58. Wong HR, Cvijanovich N, Lin R, et al: Iden-tification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 2009; 7:34
59. Byvatov E, Schneider G: Support vector machine applications in bioinformatics. Appl Bioinformatics 2003; 2:67-77
60. Vincent JL, Opal SM, Marshall JC: Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med 38:283-287